Combined Anti-CD20 and mTOR Inhibition with Factor VIII for Immune Tolerance Induction in Hemophilia A Patients with Refractory Inhibitors.

CONCLUSIONS: This regimen may be considered to induce FVIII tolerance in HA patients with refractory inhibitors. Further characterization of the FVIII-specific immune response is necessary to clarify the mechanism of immune tolerance. PMID: 31985872 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31985872?dopt=Abstract

Source: Thrombosis and Haemostasis - January 26, 2020 Category: Hematology Authors: Doshi BS, Raffini LJ, George LA Tags: J Thromb Haemost Source Type: research